Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza Vaccines | 13 | 2020 | 2941 | 1.34 | Why? |
| Influenza, Human | 18 | 2020 | 10779 | 1.08 | Why? |
| Respiratory Tract Infections | 6 | 2021 | 6817 | 0.74 | Why? |
| Materia Medica | 1 | 2018 | 30 | 0.74 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 91 | 0.69 | Why? |
| Amoxicillin | 1 | 2018 | 98 | 0.68 | Why? |
| Anti-Infective Agents | 4 | 2021 | 1766 | 0.67 | Why? |
| Soft Tissue Infections | 1 | 2018 | 116 | 0.66 | Why? |
| Severe Dengue | 1 | 2017 | 135 | 0.60 | Why? |
| Health Impact Assessment | 1 | 2017 | 181 | 0.60 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2018 | 282 | 0.59 | Why? |
| Community-Acquired Infections | 4 | 2019 | 2328 | 0.52 | Why? |
| Probiotics | 2 | 2018 | 694 | 0.51 | Why? |
| Disease Notification | 1 | 2017 | 639 | 0.45 | Why? |
| Immunity, Innate | 2 | 2021 | 6570 | 0.42 | Why? |
| Vaccination | 12 | 2021 | 19050 | 0.42 | Why? |
| Pneumonia, Bacterial | 1 | 2016 | 843 | 0.39 | Why? |
| Nursing Homes | 2 | 2018 | 4155 | 0.38 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.38 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.36 | Why? |
| Seasons | 7 | 2019 | 4071 | 0.36 | Why? |
| Ventilators, Mechanical | 1 | 2020 | 2193 | 0.34 | Why? |
| Immunization Schedule | 3 | 2019 | 1305 | 0.33 | Why? |
| Dietary Supplements | 2 | 2021 | 2251 | 0.32 | Why? |
| Epidemiological Monitoring | 3 | 2020 | 3493 | 0.30 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.28 | Why? |
| Orthomyxoviridae | 2 | 2017 | 1168 | 0.28 | Why? |
| Streptococcus pneumoniae | 3 | 2019 | 827 | 0.28 | Why? |
| Aging | 1 | 2021 | 3581 | 0.28 | Why? |
| Pneumococcal Vaccines | 2 | 2019 | 571 | 0.26 | Why? |
| Urinary Tract Infections | 2 | 2019 | 534 | 0.25 | Why? |
| Canada | 12 | 2021 | 6018 | 0.25 | Why? |
| Occupational Exposure | 2 | 2020 | 4742 | 0.24 | Why? |
| Immunogenicity, Vaccine | 1 | 2018 | 4624 | 0.24 | Why? |
| Randomized Controlled Trials as Topic | 8 | 2021 | 10649 | 0.23 | Why? |
| Pneumococcal Infections | 2 | 2019 | 562 | 0.23 | Why? |
| Skin Diseases | 1 | 2018 | 2509 | 0.23 | Why? |
| Masks | 3 | 2020 | 8528 | 0.22 | Why? |
| Critical Care | 3 | 2021 | 14081 | 0.20 | Why? |
| Carrageenan | 1 | 2021 | 123 | 0.20 | Why? |
| Observational Studies as Topic | 2 | 2018 | 1887 | 0.20 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.19 | Why? |
| Respiration, Artificial | 4 | 2020 | 22116 | 0.19 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.19 | Why? |
| Cefazolin | 1 | 2018 | 31 | 0.19 | Why? |
| Drug Resistance, Bacterial | 2 | 2019 | 1414 | 0.18 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.18 | Why? |
| Lactobacillus reuteri | 1 | 2017 | 16 | 0.18 | Why? |
| Serogroup | 2 | 2019 | 510 | 0.18 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 92 | 0.18 | Why? |
| Practice Guidelines as Topic | 7 | 2021 | 15421 | 0.18 | Why? |
| Honduras | 1 | 2017 | 117 | 0.17 | Why? |
| Frail Elderly | 2 | 2018 | 1427 | 0.17 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.17 | Why? |
| Ascites | 1 | 2017 | 65 | 0.17 | Why? |
| Equivalence Trials as Topic | 1 | 2018 | 242 | 0.17 | Why? |
| Pregnancy Complications, Infectious | 3 | 2019 | 11559 | 0.17 | Why? |
| Hospitals, Isolation | 1 | 2020 | 300 | 0.16 | Why? |
| Anti-Bacterial Agents | 5 | 2019 | 10083 | 0.16 | Why? |
| Hospitalization | 7 | 2019 | 54280 | 0.16 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.16 | Why? |
| Pneumonia, Pneumococcal | 1 | 2019 | 251 | 0.16 | Why? |
| Humans | 52 | 2021 | 930598 | 0.16 | Why? |
| Cadaver | 1 | 2020 | 626 | 0.15 | Why? |
| Vaccine Potency | 1 | 2017 | 339 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.15 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.15 | Why? |
| West Nile Fever | 1 | 2017 | 166 | 0.15 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2019 | 398 | 0.14 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.13 | Why? |
| Multicenter Studies as Topic | 2 | 2018 | 2437 | 0.13 | Why? |
| Public Health | 3 | 2020 | 16359 | 0.13 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.13 | Why? |
| Surgical Wound Infection | 1 | 2018 | 501 | 0.13 | Why? |
| Adrenal Cortex Hormones | 2 | 2021 | 6537 | 0.13 | Why? |
| Vaccines, Attenuated | 1 | 2018 | 952 | 0.12 | Why? |
| Decision Support Systems, Clinical | 1 | 2018 | 551 | 0.12 | Why? |
| Ontario | 2 | 2018 | 1966 | 0.12 | Why? |
| Bias | 1 | 2018 | 1109 | 0.12 | Why? |
| Odds Ratio | 3 | 2019 | 5861 | 0.12 | Why? |
| Pilot Projects | 3 | 2018 | 5182 | 0.12 | Why? |
| Treatment Outcome | 10 | 2021 | 51732 | 0.11 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.11 | Why? |
| Intensive Care Units | 5 | 2021 | 29594 | 0.11 | Why? |
| Platelet Count | 1 | 2017 | 1381 | 0.11 | Why? |
| Biomarkers | 1 | 2014 | 23361 | 0.11 | Why? |
| Vaccines, Inactivated | 1 | 2018 | 1562 | 0.11 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.11 | Why? |
| Uncertainty | 2 | 2021 | 1888 | 0.11 | Why? |
| Vaccination Refusal | 1 | 2019 | 831 | 0.11 | Why? |
| Rheumatology | 1 | 2021 | 1213 | 0.11 | Why? |
| Aged | 15 | 2021 | 215776 | 0.10 | Why? |
| Disease Outbreaks | 2 | 2017 | 27595 | 0.10 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.10 | Why? |
| Influenza A virus | 2 | 2019 | 2234 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| Female | 22 | 2020 | 380317 | 0.10 | Why? |
| Cytomegalovirus | 1 | 2014 | 600 | 0.10 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2018 | 2984 | 0.09 | Why? |
| Pneumonia | 2 | 2019 | 5652 | 0.09 | Why? |
| Respiratory Protective Devices | 1 | 2020 | 1637 | 0.09 | Why? |
| Cytomegalovirus Infections | 1 | 2014 | 667 | 0.09 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.09 | Why? |
| Male | 19 | 2020 | 367725 | 0.08 | Why? |
| Evidence-Based Medicine | 4 | 2021 | 3228 | 0.08 | Why? |
| Vaccines, Conjugate | 2 | 2019 | 328 | 0.08 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.08 | Why? |
| Health Personnel | 4 | 2020 | 29646 | 0.08 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.08 | Why? |
| Adolescent | 9 | 2019 | 86841 | 0.08 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.07 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.07 | Why? |
| Diarrhea | 1 | 2017 | 2743 | 0.07 | Why? |
| Meta-Analysis as Topic | 1 | 2012 | 1289 | 0.07 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.07 | Why? |
| Pandemics | 13 | 2020 | 389249 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.07 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.07 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2018 | 572 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Multivariate Analysis | 1 | 2014 | 5440 | 0.06 | Why? |
| Phenotype | 1 | 2014 | 4037 | 0.06 | Why? |
| Universities | 1 | 2018 | 4374 | 0.06 | Why? |
| Survival Analysis | 1 | 2016 | 7592 | 0.06 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.06 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.06 | Why? |
| Adult | 13 | 2020 | 244371 | 0.06 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2018 | 88759 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3832 | 0.05 | Why? |
| Middle Aged | 13 | 2019 | 270681 | 0.05 | Why? |
| Pregnancy | 3 | 2019 | 23879 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Child | 3 | 2018 | 70012 | 0.05 | Why? |
| Students | 1 | 2018 | 5255 | 0.05 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.05 | Why? |
| Drug Combinations | 2 | 2020 | 3852 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 4 | 2020 | 12361 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.05 | Why? |
| Child, Preschool | 3 | 2018 | 36283 | 0.05 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.05 | Why? |
| Mortuary Practice | 1 | 2020 | 110 | 0.05 | Why? |
| Pyelonephritis | 1 | 2019 | 66 | 0.05 | Why? |
| Young Adult | 6 | 2019 | 93724 | 0.05 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.05 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2020 | 426 | 0.04 | Why? |
| Botswana | 1 | 2017 | 98 | 0.04 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2020 | 265 | 0.04 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.04 | Why? |
| Cohort Studies | 3 | 2019 | 36005 | 0.04 | Why? |
| Respiratory Insufficiency | 1 | 2019 | 7301 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2020 | 418 | 0.04 | Why? |
| Serotyping | 1 | 2017 | 154 | 0.04 | Why? |
| Alberta | 1 | 2018 | 375 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Absenteeism | 1 | 2019 | 287 | 0.04 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.04 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 350 | 0.04 | Why? |
| T-Lymphocytes | 1 | 2014 | 6670 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.04 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.04 | Why? |
| Likelihood Functions | 1 | 2018 | 719 | 0.04 | Why? |
| Research Design | 1 | 2012 | 5830 | 0.04 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.04 | Why? |
| Immunization Programs | 2 | 2018 | 2006 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.03 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.03 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Ventilation | 1 | 2021 | 1145 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.03 | Why? |
| Adenosine Monophosphate | 2 | 2021 | 5652 | 0.03 | Why? |
| Alanine | 2 | 2021 | 5687 | 0.03 | Why? |
| Hemodynamics | 1 | 2021 | 1562 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.03 | Why? |
| Advisory Committees | 1 | 2019 | 1418 | 0.03 | Why? |
| Influenza B virus | 1 | 2017 | 815 | 0.03 | Why? |
| Immunity, Herd | 1 | 2019 | 1011 | 0.03 | Why? |
| SARS Virus | 2 | 2006 | 13021 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Patient Positioning | 1 | 2021 | 1505 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| Communicable Diseases, Emerging | 1 | 2004 | 2523 | 0.02 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.02 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 13720 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Pregnant Women | 1 | 2019 | 2535 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.02 | Why? |
| Infant | 2 | 2017 | 30274 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Comorbidity | 2 | 2019 | 34796 | 0.02 | Why? |
| Aerosols | 1 | 2020 | 5393 | 0.02 | Why? |
| Protective Clothing | 1 | 2006 | 468 | 0.01 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.01 | Why? |
| Costs and Cost Analysis | 1 | 2004 | 694 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Cluster Analysis | 1 | 2006 | 3001 | 0.01 | Why? |
| Interviews as Topic | 1 | 2006 | 1952 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2004 | 23402 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Reagent Kits, Diagnostic | 1 | 2004 | 2149 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2004 | 7220 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2006 | 9706 | 0.00 | Why? |
| RNA, Viral | 1 | 2004 | 32276 | 0.00 | Why? |